Talking Ketamine Podcast

Explore the cutting-edge science and therapeutic potential of ketamine. Talking Ketamine offers evidence-based discussions to demystify its role in mental health and beyond, providing informed insights into this powerful compound. Each episode explores a recent scientific study that explores an interesting aspect of ketamine treatment, ketamine therapy, and ketamine use in mental health. The podcast has covered topics ranging from ketamine and music to ketamine's surprising help in battling some cancers. Most of the papers covered are cutting edge science so you may not want to make medical decisions from them. But, each piece of evidence, good or bad, big or small, guides us to a better understanding of this miraculous medicine. If you are interested in ketamine research because you suffer from MDD or are having thoughts of suicide, please dial 988 or visit https://988lifel

Talking Ketamine Podcast is a health podcast hosted by Talking Ketamine, with 81 episodes on record and a Required Pod Score of 80.

Talking Ketamine hosts Talking Ketamine Podcast, a health show with 81 episodes published.

Our AI reads these to draft pitches. Use them as grounding for a pitch that cites a real guest and a specific topic.

• 

  Episode #83

  Bridging the Antidepressant Gap

  Oct 3, 202619 min

  The most dangerous window in severe depression occurs during the four to eight week lag before conventional antidepressants take effect, a vulnerable period where suicide risk peaks. A breakthrough randomized controlled trial demonstrates that frontline add-on intravenous ketamine completely eliminates this agonizing delay, delivering meaningful clinical relief within 48 hours. Discover how just four infusions achieved a 58% response rate, cleared suicidal ideation to absolute zero within five days, and sustained recovery at four weeks. We also unpack the vital anxiety paradox that dictates who should, and who should not, receive this rapid intervention. Tune in to explore how emergency psychiatry can shift from passive observation into proactive, rapid neuroplastic healing. Resources: Prakash, A., Mahapatra, P., Pattnaik, J. I., Panda, U. K., & Das, S. K. (2026). Add-on intravenous ketamine eliminates treatment lag period in severe non-treatment-resistant major depression: Rapid antidepressant and anti-suicidal effects – A randomized controlled trial. *Indian Journal of Psychiatry*, *68*(9), 776–783. https://doi.org/10.4103/indianjpsychiatry_845_25

  ListenShow Notes
• 

  Episode #82

  The Brain's Chemical Seesaw

  Sep 28, 202620 min

  ## Episode 82: The Brain's Chemical Seesaw ### Enticing One-Sentence Description What if ketamine doesn't relieve depression by permanently altering brain chemicals, but by forcing a stuck neural seesaw to recalibrate in real time? We dive into a landmark meta-analysis of living brain imaging studies to reveal why lasting relief is rooted in a dynamic balancing act mid-infusion—and how individual baseline chemistry could finally eliminate psychiatric guesswork. ### Engaging Description For decades, depression was blamed on a chemical deficit, but what if brain imaging has been taking snapshots at the wrong times? A landmark systematic review reveals that ketamine leaves 24-hour resting neurotransmitter levels unchanged—because its true antidepressant power is a dynamic balancing act unfolding mid-infusion. Discover how acute glutamate cycling disrupts rigid neural ruts to reset the excitation-inhibition balance, and why baseline Glx/GABA ratios in the anterior cingulate cortex predict clinical remission. We unpack how these real-time neurochemical shifts validate the patient experience and open doors for precision psychiatry. Tune in to explore why ketamine tunes the brain rather than applying a blunt chemical fix. Resources: Singh, B., Ali, H. M., Miola, A., Nunez, N. A., Fogaça, M. V., Jelen, L. A., Prokop, L. J., Sanacora, G., Zarate, C. A., Jr., Frye, M. A., & Port, J. D. (2026). Modulation of GABA and glutamate by ketamine in depression: A systematic review and meta-analysis of magnetic resonance spectroscopy studies. *Neuropsychopharmacology*. Advance online publication. https://doi.org/10.1038/s41386-026-02562-4 ### Categories - Clinical Applications - Ketamine Therapy - Neuroscience & Brain Function ### Tags Antidepressant Effects, Biomarkers, Brain Changes, Clinical Applications, Depression, Glutamate, Human Trials, Infusion Therapy, Ketamine, Ketamine Therapy, Mental Health, Neuroplasticity, Neuroscience & Brain Function, Systematic Review, Treatment-Resistant Depression (TRD) ### Bluesky Post Does ketamine just boost brain chemicals? Ep 82 explores new research showing ketamine rebalances neural circuits mid-infusion. ⚖️ Dynamic glutamate-GABA reset Baseline chemistry predicts relief [Link] #Ketamine #Neuroscience #MentalHealth ### Video Stream [Watch Video Stream](https://customer-e74b32de40b3ccf4220e6a9a542fa8e5.cloudflarestream.com/984625bc1447c58e7bd239a1d537454e/manifest/video.m3u8)

  ListenShow Notes
• 

  Episode #81

  Does Ketamine Damage the Brain?

  Sep 22, 202622 min

  Sensational headlines warn that ketamine shrinks brain tissue, but what actually happens to human neuroanatomy under chronic, extreme exposure? A landmark systematic review analyzing brain scans from hundreds of heavy recreational users reveals exactly where therapeutic healing ends and structural degradation begins. Discover how years of multi-gram daily abuse erode cortical gray matter and fray white matter wiring through glutamate excitotoxicity, while low-dose medical treatments protect and rebuild neural networks. We unpack critical research caveats like polydrug use and reveal why the dose truly makes the poison. Tune in to separate internet panic from clinical reality and protect your peace of mind. Resources: Strous, J. F. M., Weeland, C. J., van der Draai, F. A., Daams, J. G., Denys, D., Lok, A., Schoevers, R. A., & Figee, M. (2022). Brain changes associated with long-term ketamine abuse, a systematic review. Frontiers in Neuroanatomy , 16 , Article 795231. https://doi.org/10.3389/fnana.2022.795231

  ListenShow Notes
• 

  Episode #80

  Ketamine's Rapid Pain Reset

  Sep 12, 202618 min

  When severe nerve pain turns the body's alarm system into an unceasing siren, can just five days of intravenous ketamine force the brain to unlearn the agony? We dive into a head-to-head clinical trial pitting ketamine against lidocaine to uncover how a rapid molecular circuit breaker delivers months of life-changing relief. ### Engaging Description When severe neuropathic pain turns the nervous system into an unceasing alarm, conventional daily medications fail over half of all sufferers. In a head-to-head clinical trial, researchers pitted five consecutive days of intravenous ketamine directly against lidocaine to discover which could halt treatment-resistant nerve pain faster. Ketamine emerged as an explosive sprinter, delivering clinically meaningful relief in over 86% of patients by week two compared to just 50% for lidocaine. Remarkably, both therapies converged at a 60% sustained success rate by six months, highlighting critical trade-offs between central and peripheral pathways. Tune in to discover how targeted infusions can disrupt entrenched pain circuits and restore lasting hope. Resources: Sucu, M. G., Yavuz Mollavelioğlu, T., Akyüz Yildirim, A., & Çelebi, N. (2026). Short- and midterm analgesic outcomes of ketamine versus lidocaine infusion in chronic peripheral neuropathic pain: A retrospective study. Pain Research and Management , 2026 , Article 7897619. https://doi.org/10.1155/prm/7897619

  ListenShow Notes
• 

  Episode #79

  The Oral Ketamine Guide

  Sep 7, 202624 min

  While patented nasal sprays and hospital IV infusions carry steep price tags, a comprehensive prescriber's guide reveals that generic injectable ketamine can be repurposed into a safe oral drink for under fifty cents. This protocol breaks open rapid psychiatric care for individuals trapped in severe, suicidal depressive crises where specialized clinical suites simply do not exist. Learn how slowly sipping the solution over twenty to thirty minutes flattens blood plasma spikes to minimize dissociation, why a trusted companion provides an indispensable psychological anchor, and how oral dosing acts as a rapid bridge while traditional antidepressants take hold. Tune in to discover how this practical clinical blueprint is transforming affordable mental health care. Resources: Andrade, C. (2026). The prescriber’s guide to oral ketamine for patients with major depressive illness: Principles and practice. The Journal of Clinical Psychiatry , 87 (3), Article 26f16110. https://doi.org/10.4088/JCP.26f16110

  ListenShow Notes

Based on semantic analysis of episode topics and host coverage, this show is a strong guest fit for executives in:

Industry fit is computed by PitchCentric using vector embeddings of the show's episode catalog.